These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 14508717)

  • 1. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE; Keating GM
    BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
    J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G
    Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
    Crawford J
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J
    Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegfilgrastim.
    Curran MP; Goa KL
    Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
    BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim.
    Willis F; Pettengell R
    Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
    Molineux G
    Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
    Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
    Mucenski JW; Shogan JE
    J Manag Care Pharm; 2003; 9(2 Suppl):10-4. PubMed ID: 14613339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T; Densmore JJ
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.